GSK’s drug gepotidacin shows efficacious results as a treatment for uncomplicated urinary tract infections (uUTIs) in female adults. In the first half of next year, the business plans to submit regulatory applications to the US Food and Drug Administration for gepotidacin, which, if authorised, may become the first medication in a new class of oral antibiotics for uUTIs in individuals aged 20 or over.
Related: GSK snags FDA’s approval for single-vial version Menveo vaccine
Around 80% of UTI infections, which affect an estimated 150 million individuals annually, are brought on by E. coli. This frequently contains bacteria that are difficult to treat and resistant to commonly used antibiotics. Gepotidacin will reduce the chance of the disease becoming worse.
Read More from PMLive
